In MSM, long­acting injectable PrEP could outperform oral PrEP

Among men who have sex with men, the use of long-acting injectable pre-exposure prophylaxis, or PrEP, to prevent HIV infection has the potential to reduce HIV transmission more than oral PrEP, according to the results of a modelling simulation published in The Lancet HIV. Continue reading

PrEP Gay men get less HIV but more STIs after starting PrEP, meta-analysis find

A meta-analysis of 17 studies of HIV pre-exposure prophylaxis (PrEP) in gay men and other men who have sex with men (MSM) has found that, while PrEP protected them from HIV, the proportion diagnosed with gonorrhoea, chlamydia or syphilis increased significantly in the period between starting PrEP and follow-up, with an average length of time on PrEP at follow-up of six months. The headline figures come from eight studies that recorded both STI diagnoses at both baseline and during follow-up. On average, after starting PrEP, there was: an increase of 24% in diagnoses of any of these three STIs a 39% increase in rectal STIs a 59% increase in rectal chlamydia.  All of these increases were statistically significant.  Continue reading

Many young MSM discontinue PrEP

A third of young men who have sex with men (MSM) who take pre-exposure prophylaxis (PrEP) discontinue it within a six-month period, investigators from the United States report in AIDS and Behavior. Common reasons for stopping included being unable to get an appointment with a doctor and problems with insurance coverage Continue reading